Background: Previous studies suggested that somatostatin given before endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis. However, the routine use of somatostatin in all patients undergoing ERCP is not likely to be cost effective. This study evaluated whether intravenous bolus somatostatin given after diagnostic cholangiopancreatography could reduce the incidence of pancreatitis in a group of patients undergoing therapeutic ERCP procedures. Methods: In a randomised, double blind, controlled trial, the effect of intravenous bolus somatostatin 250 μg given immediately after diagnostic cholangiopancreatography was compared with that of placebo in patients who required endoscopic sphincterotomy or other therapeutic procedures. The primary end point was the incidence of post-ERCP clinical pancreatitis, and a secondary end point was the incidence of hyperamylasemia. Results: A total of 270 patients were randomised. The somatostatin group (n = 135) and the placebo group (n = 135) were comparable in age, sex, indications for treatment, and types of procedure. The frequencies of clinical pancreatitis (4.4% v 13.3%; p = 0.010) and hyperamylasemia (26.0% v 38.5%; p = 0.036) were both significantly lower in the somatostatin group compared with the placebo group. Conclusions: A single dose of intravenous bolus somatostatin, given immediately after diagnostic cholangiopancreatography, is effective in reducing the incidence of pancreatitis after therapeutic ERCP. This novel approach of administering prophylactic somatostatin may offer a cost effective prophylaxis for post-ERCP pancreatitis.

Gut

Biological and medical sciences; Investigative techniques, diagnostic techniques (general aspects); Medical sciences; Endoscopy; Digestive system. Abdomen; Acute Disease; Amylases - blood; Hyperamylasemia - prevention & control; Injections, Intravenous; Double-Blind Method; Pancreatitis - etiology; Hormones - administration & dosage; Humans; Middle Aged; Somatostatin - administration & dosage; Cholangiopancreatography, Endoscopic Retrograde - adverse effects; Male; Pancreatitis - prevention & control; Pancreatitis - blood; Female; Aged; Endoscopic retrograde cholangiopancreatography; Usage; Care and treatment; Complications; Pancreatitis; Colorectal diseases; Research; Patients; Prevention; Gastrointestinal diseases; Causes of; Physiological aspects; Dosage and administration; Somatostatin; Health aspects; Testing; Studies; Heart attacks; Rodents; Mortality; Drug dosages; Risk factors; Index Medicus; Abridged Index Medicus; endoscopic retrograde cholangiopancreatography; pancreatitis; Pancreas; somatostatin; China; Human; Cholangiopancreatography; Iatrogenic; Intravenous administration; Radiodiagnosis; Retrograde; Peptide hormone; Pancreatitis; Biliary tract disease; Prevention; Randomization; Digestive diseases; Complication; Clinical trial; Endoscopy; Somatostatin; Pancreatic disease

MEDLINE; Medline Complete; MEDLINE with Full Text; PubMed; MEDLINE (Ovid); CrossRef; ProQuest Central Student; ProQuest Central Essentials; ProQuest Health & Medical Complete (Alumni); ProQuest AP Science; ProQuest Central (Alumni Edition); SciTech Premium Collection; ProQuest Natural Science Collection; ProQuest Central China; ProQuest Central; Health Research Premium Collection; Health and Medicine Complete (Alumni Edition); Natural Science Collection; ProQuest Central Korea; Biological Science Collection; ProQuest Medical Library (Alumni); ProQuest Science Journals (Alumni Edition); ProQuest Biological Science Collection; ProQuest Central Basic; ProQuest Science Journals; ProQuest One Academic Eastern Edition; ProQuest Hospital Collection; Health Research Premium Collection (Alumni); Biological Science Database; ProQuest SciTech Collection; ProQuest Hospital Collection (Alumni); ProQuest Health & Medical Complete; ProQuest Medical Library; ProQuest One Academic UKI Edition; BMJ Journals; ProQuest One Academic; ProQuest Central (Alumni); MEDLINE - Academic